Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇦🇺
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland, Australia
🇧🇪Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale, Belgium
🇧🇪AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen, Belgium
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- North Estonia Medical Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06505369
- Locations
- 🇳🇴
Oslo University Hospital, Oslo Myeloma Centre, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇩🇰Vejle hospital, Vejle, Denmark
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 39
- Registration Number
- NCT06504199
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
🇨🇳Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06441097
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 45
- Registration Number
- NCT06409702
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06353022
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
🇫🇷CH Lyon Sud, Lyon, France
🇫🇷CH de la Côte Basque, Bayonne, France
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06348147
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 80
- Registration Number
- NCT06324266
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.